Novo Nordisk A/S
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Novo Nordisk A/S
Increasingly looking to China to commercialize their latest therapies, multinationals may be leaping into unknown waters to navigate an intellectual property judiciary and administrative maze, in a country where some copy drugs have been approved before patent expiry. With a government trying to balance innovation and access, two recent rulings involving AstraZeneca shed rare light onto China’s protections for innovation, with advisors pointing to challenges and success factors.
With still no approved therapy for non-alcoholic steatohepatitis, Intercept, Madrigal, Inventiva and others used the liver meeting to build the cases for their NASH candidates.
With an FDA clinical hold lifted, CymaBay plans to initiate a new Phase III in primary biliary cholangitis early in 2021. It also hopes to partner the drug in NASH with a company developing a metabolic drug for the disease.
In an interview with Medtech Insight, Glooko CEO Russ Johannesson outlines the company’s growth opportunities, expansion plans beyond diabetes and financing plans.
- Large Molecule
- Other Names / Subsidiaries
- Corvidia Therapeutics
- Neose Technologies, Inc.
- Novo Holdings A/S
- Novo Nordisk Pharmaceuticals, Inc.
- Pharmaero Aps
- Xellia Pharmaceuticals ApS
- Ziylo Ltd